Trevi Therapeutics, Inc. Common Stock TRVI
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T19:51:55.838Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T19:51:21.609039831Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T19:51:55.708187+00:00
Trevi Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 9.67 | 500.0% | 41.9% | |||
| 25Δ | 10.98 | 400.1% | 32.4% | |||
| 30Δ | 11.84 | 343.2% | 26.3% | |||
| 35Δ | 24.40 | 508.2% | 90.2% | 12.70 | 287.1% | 20.2% |
| 40Δ | 18.95 | 395.6% | 50.5% | |||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | ||||||
| 60Δ | ||||||
| 65Δ | 12.87 | 189.6% | 8.2% | 15.15 | 140.6% | 4.6% |
| 70Δ | 12.52 | 169.8% | 6.1% | 15.35 | 128.4% | 3.7% |
| 75Δ | 12.17 | 149.9% | 4.1% | 15.54 | 116.1% | 2.8% |
| 80Δ | 11.78 | 138.9% | 2.7% | 15.74 | 103.9% | 1.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.67
- IV
- 500.0%
- B/E move
- 41.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.98
- IV
- 400.1%
- B/E move
- 32.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.84
- IV
- 343.2%
- B/E move
- 26.3%
35Δ
- Pseudo strike
- 24.40
- IV
- 508.2%
- B/E move
- 90.2%
- Pseudo strike
- 12.70
- IV
- 287.1%
- B/E move
- 20.2%
40Δ
- Pseudo strike
- 18.95
- IV
- 395.6%
- B/E move
- 50.5%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 12.87
- IV
- 189.6%
- B/E move
- 8.2%
- Pseudo strike
- 15.15
- IV
- 140.6%
- B/E move
- 4.6%
70Δ
- Pseudo strike
- 12.52
- IV
- 169.8%
- B/E move
- 6.1%
- Pseudo strike
- 15.35
- IV
- 128.4%
- B/E move
- 3.7%
75Δ
- Pseudo strike
- 12.17
- IV
- 149.9%
- B/E move
- 4.1%
- Pseudo strike
- 15.54
- IV
- 116.1%
- B/E move
- 2.8%
80Δ
- Pseudo strike
- 11.78
- IV
- 138.9%
- B/E move
- 2.7%
- Pseudo strike
- 15.74
- IV
- 103.9%
- B/E move
- 1.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 61.13% | |
| 71.17% | |
| 69.08% | |
| 81.86% | |
| 76.38% | |
| 74.81% | |
| 66.77% | |
| 67.53% | |
| 64.32% | |
| 73.01% |
Biotechnology
TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic…
More →TTRX
Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village,…
More →TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The…
More →TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
More →TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The…
More →UNCY
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia.…
More →